Cenobamate
- Generic Name
- Cenobamate
- Brand Names
- Ontozry, XCopri, Xcopri 250 Mg Maintenance Pack, Xcopri Titration Pack - 12.5 Mg (14), 25 Mg (14) 28 Count
- Drug Type
- Small Molecule
- Chemical Formula
- C10H10ClN5O2
- CAS Number
- 913088-80-9
- Unique Ingredient Identifier
- P85X70RZWS
- Background
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABA and inhibits voltage gated sodium channels.
Cenobamate was granted FDA approval on 21 November 2019.
- Indication
Cenobamate is indicated for the treatment of partial onset seizures in adults.
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- -
Cenobamate Open-Label Extension Study for YKP3089C025
- Conditions
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT03961568
- Locations
- 🇺🇦
Municipal Institution Zaporizhzhia Regional Clinical Hospital of Zaporizhzhia Regional Council, Zaporozhye, Zaporizhzhya, Ukraine
🇺🇦Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnikov", Regional Center, Dnipropetrovs'k, Ukraine
🇺🇦Regional Psyconeurology Hospital #3, Ivano-Frankivs'k, Ukraine
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT03678753
- Locations
- 🇺🇸
Ohio Health Research and Innovation Institute, Columbus, Ohio, United States
🇺🇸Duke University Children's Health Center, Durham, North Carolina, United States
🇺🇸University of Toledo, Toledo, Ohio, United States
A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
- Conditions
- Interventions
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03509285
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Inc, Overland Park, Kansas, United States
🇨🇦INC Research, Inc., Toronto, Ontario, Canada
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions
- Conditions
- Interventions
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- SK Life Science, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03234699
- Locations
- 🇺🇸
Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.